NUTRIBAND INC. ITEM 3.02. Unregistered Sales of
The following table sets forth the sales of unregistered securities since the Company's last report filed under this item.
Total Offering
Price/
Title and Principal Underwriting
Date Amount (1) Purchaser Underwriter Discounts
Gareth
10,000 shares Sheridan, CEO $15.00 per
January 5, 2021 of common stock and Director NA share/NA
Sean Gallagher,
Executive
10,000 shares Chairman and $15.00 per
January 5, 2021 of common stock Director NA share/NA
10,000 shares Serguei Melnik, $15.00 per
January 5, 2021 of common stock Director NA share/NA
Michael Myer,
President of
5,000 shares of Pocono Pharma $15.00 per
January 5, 2021 common stock and Director NA share/NA
12,500 shares Radu Bujoreanu, $15.00 per
January 5, 2021 of common stock Director NA share/NA
10,000 shares Steven P. $15.00 per
January 5, 2021 of common stock Damon, Director NA share/NA
5,000 shares of Michael Doron, $15.00 per
January 5, 2021 common stock Director NA share/NA
12,5000 shares Mark Hamilton, $15.00 per
January 5, 2021 of common stock Director NA share/NA
12,500 shares Stefan Mancas, $15.00 per
January 5, 2021 of common stock Director NA share/NA
Vsevolod
5,000 shares of Grogore, $15.00 per
January 5, 2021 common stock Director NA share/NA
Patrick Ryan,
Chief
5,000 shares of Technical $15.00 per
January 5, 2021 common stock Officer NA share/NA
Gerald Goodman,
10,000 shares Chief Financial $15.00 per
January 5, 2021 of common stock Officer NA share/NA
Alan Smith,
Chief Operating
Officer and
6.825 shares of President of 4P $15.00 per
January 5, 2021 common stock Therapeutics NA share/NA
Vitalie
5,000 shares of Botgros, $15.00 per
January 5, 2021 common stock Consultant NA share/NA
6,000 shares of Thomas Cooney, $15.00 per
January 5, 2021 common stock Director NA share/NA
5,000 shares of Jay Moore, $15.00 per
January 5, 2021 common stock Director NA share/NA
(1) The issuances to directors and management and consultants are viewed by the
Company as exempt from registration under the Securities Act of 1933, as
amended ("Securities Act"), alternatively, as transactions either not
involving any public offering, or as exempt under the provisions of
Regulation D, Regulation S or Rule 701 promulgated by the SEC under the
Securities Act.
1© Edgar Online, source
